|
|
||||||||
1 From the The Department of Biological Sciences, The University of Delaware, Newark; 2 The Departments of Ophthalmology and Molecular Genetics, Albert Einstein College of Medicine, Bronx, New York; and the 3 Laboratory of Molecular and Developmental Biology, National Eye Institute, Bethesda, Maryland.
| Abstract |
|---|
|
|
|---|
METHODS. Transgenic mice were created harboring the
A-crystallin promoter
linked to a cDNA encoding either a truncated Pax-6 without the C
terminus (paired domain [PD] + homeodomain) or Pax-6 consisting of
only the PD. The phenotype of the resultant animals was investigated by
light and electron microscopy as well as atomic absorption
spectroscopy.
RESULTS. Two lines of PD + HD mice and three lines of PD mice were generated, all of which exhibit posterior nuclear and/or cortical cataracts of variable severity. The lenses from mice transgenic for either Pax-6 truncation are smaller and more hydrated than normal. Morphologically, the mice expressing the PD + HD of Pax-6 have swollen lens fibers with attenuated ball-and-socket junctions. In contrast, the lenses from mice overexpressing the PD of Pax-6 have posterior nuclear cataracts composed of cell debris, whereas the remaining fiber cells appear generally normal.
CONCLUSIONS. The presence of truncated Pax-6 protein in the lens is sufficient to induce cataract in a wild-type genetic background. The simplest explanation for this phenomenon is a dominantnegative effect; however, a number of other possible mechanisms are presented.
| Introduction |
|---|
|
|
|---|
The Pax-6 protein consists of at least three functional domains. The paired domain (PD), named for its similarity to the Drosophila protein Paired, consists of two subdomains (PAI and RED), each of which contribute to the DNA binding specificity of Pax-6.10 11 The homeodomain (HD) functions as a dimerization as well as a DNA-binding domain that can act independently and in cooperation with the PD to increase the spectrum of possible DNA-binding sites.10 The C terminus of Pax-6 is rich in proline, serine, and threonine amino acids and is thus denoted the PST domain. The PST domain is critical for the full range of Pax-6 function and appears to be a transcriptional activation domain (AD).5
More than 70 different mutations affecting the eye have been identified in the Pax-6 gene of vertebrates, ranging from the complete deletion of one allele12 to missense mutations.13 Different eye tissues have different sensitivity to alterations both in the amount of functional Pax-6 protein present14 and in Pax-6 protein structure.11 15 The most commonly identified mutations result in the premature termination of mRNA translation and in the production of truncated Pax-6 proteins.3 In patients with classic aniridia, the severity of the iris and corneal pathology does not correlate with the type of Pax-6 mutation, suggesting that the disease is caused by a haploinsufficiency of Pax-6 function.1 However, biochemical characterization of mutant Pax-6 proteins indicates that some can maintain partial function.5 16 17 18
Early in development, Pax-6 is critical for the induction of the lens
from the head ectoderm.6
Later in lens development, Pax-6
appears to transactivate the expression of a number of crystallin
genes, including
A-,19
B-,20
-,21
and
-crystallin,22
and to repress
the expression of the lens fiber cellspecific ßB1-crystallin
gene.17
The importance of Pax-6 in the lens after
induction can be inferred from the observation that aniridia patients
commonly develop cataracts.2
Although it has been
suggested that these cataracts arise secondary to the other eye
pathologies of aniridia patients,3
a family has been
reported with relatively normal eye anatomy except for the presence of
bilateral congenital cataract. In this family, a mutation results in
the deletion of the last 69 amino acids of the Pax-6 AD.5
This is consistent with the observation that aniridia patients with
mutations in the AD of Pax-6 are more likely to suffer from congenital
cataracts than patients with other types of Pax-6
alterations.23
If cataracts are common in aniridia patients that express truncated Pax-6 proteins, it is possible that the mutant protein interferes with the function of protein expressed from the normal allele. This hypothesis is supported by the fact that truncated Pax-6 proteins bind DNA with higher affinity than wild-type Pax-6 and can act as dominantnegative repressors of Pax-6 function in tissue culture.18 Thus, we tested whether truncated forms of Pax-6 could interfere with lens development and/or function in vivo, by using transgenic mouse technology.
| Materials and Methods |
|---|
|
|
|---|
286), and pKW10 expressing the PD of Pax-6 (the N-terminal 140
amino acids; pP6
140) have been described previously.17
pCMVßGal was purchased from Clontech (Palo Alto, CA).
N/N1003a cells, an established rabbit lens epithelial cell line, (a
gift from John Reddan, Oakland University, Rochester, MI) were
maintained as described.24
TN4-1 cells, a
T-antigentransformed mouse lens epithelial cell line, were maintained
as described.25
Chinese hamster ovary (CHO) cells, an
established fibroblast cell line, (a gift from Ulhas Naik; The
University of Delaware) were maintained as described.26
3T3-Tag, a T-antigentransformed version of the mouse fibroblast cell
line 3T3, (a gift of Daniel Simmons; The University of Delaware) were
maintained as described.27
For all transfections, all
cells were plated at a density of 7.5 x 105
per 60-mm dish. The next day, the cells were fed fresh media, and
transfections were performed with 10 µg promoter/CAT plasmid, 1 µg
pCMVßGal, and various amounts of expression vector using cationic
liposomes (Lipofectamine; Life Technologies, Gaithersburg, MD) as
described.28
Production of Transgenic Mice
The plasmid pACP2 (a gift of J. Fielding Hejtmancik, National Eye
Institute) containing the mouse
A-crystallin promoter
(-342/+49),29
the simian virus (SV)40 small T-antigen
intron and polyadenylation signal were modified by the addition of a
polylinker downstream of the
A-crystallin promoter containing
ClaI, BclI, XhoI, ApaI,
HindIII, SpeI, and BglII sites and
transformed into DM1 competent cells (Life Technologies, Gaithersburg,
MD) to create the plasmid pACP3. Pax-6 cDNAs (full length), PD + HD
(amino acid [aa] 1286) and PD (aa 1140) were removed from pPax-6,
pP6
286, or pP6
140 by digestion with BamHI and
HindIII and were then ligated into the
BclIHindIII site of pACP3. The fragment
containing the
A-crystallin promoter, the Pax-6 coding sequences,
and the SV40 small T-antigen intron and polyadenylation sequence was
liberated from the resultant plasmids and purified using glass
milk.30
The resultant fragment was used by the National
Eye Institute transgenic mouse facility to generate transgenic mice
(strain FVB/N) by pronuclear injection of fertilized eggs, as
described.30
Transgenic animals were identified by PCR
analysis of DNA obtained by tail biopsy using primers generated from
the SV40 small T-antigen intron as described.31
All
experiments using animals were approved by the National Eye Institute
and University of Delaware institutional review boards and conformed
with the ARVO Statement for the Use of Animals in Ophthalmic and Vision
Research.
Gross Morphology
Mice were killed by cervical dislocation and the eyes enucleated
and fixed in 4% neutral buffered formalin. After three hours, the lens
was removed and photographed with a dissecting microscope (Stemi SV11
apo; Carl Zeiss, Thornwood, NY) fitted with a Pixera digital camera
(Pixera, Los Gatos, CA) and ring light illumination.
Histologic Analysis
Mice were killed by cervical dislocation or decapitation, and the
eyes enucleated and transferred to 4% neutral buffered formalin. After
18 hours of fixation, the eyes were transferred to 70% ethanol and
stored until paraffin embedding. Six-micrometer-thick sections were
prepared and stained with hematoxylin and eosin by standard methods.
Immunocytochemistry
The expression and localization of truncated Pax-6 proteins in the
lens was determined by indirect immunofluorescence using a pan-specific
PD primary antibody (1:1000 dilution, Bios, Prague, The Czech Republic)
and rhodamine red Xlabeled anti-rabbit IgG (Jackson ImmunoResearch,
West Grove, PA) on paraffin-embedded lens tissue from 12-week-old adult
mice. The resultant fluorescence was detected on a confocal microscope
(510 LSM; Zeiss) configured with an argon-krypton laser (488 nm and 568
nm excitation lines).
Lens Protein Analysis
Mice were killed by cervical dislocation, the eyes enucleated and
lenses dissected. Both lenses from the same animal were homogenized in
200 µl of a buffer containing 20 mM sodium phosphate and 1 mM EGTA
(pH 7.0). The soluble and insoluble fractions were separated by
centrifugation and the concentration of the soluble proteins determined
by the BioRad protein assay (Bio-Rad, Hercules, CA). The crystallin
profile of lenses was determined by electrophoresing 30 µg soluble
protein on a 15% sodium dodecyl sulfatepolyacrylamide gel
electrophoresis (SDS-PAGE) gel followed by staining with Coomassie
blue. Western blot analyses were performed by electrophoresis of 100
µg soluble protein or 10 µg
TN4-1 cell extract on a 12%
SDS-PAGE gel, transfer of the separated protein to nitrocellulose, and
immunodetection of Pax-6 PD containing proteins using the anti-PD
antibody at 1:5000 dilution followed by detection with enhanced
chemiluminescence (AmershamPharmacia, Piscataway, NJ).
Scanning Electron Microscopy
Mice were killed by cervical dislocation, the eyes enucleated and
transferred to 0.08 M sodium cacodylate, 1.25% glutaraldehyde, 1%
paraformaldehyde (pH 7.3). After several hours of fixation, lenses were
excised from the eyes and placed in fresh fixative for 48 hours. After
fixation, the lens capsule and outermost layer of fiber cells were
dissected from the lens. The peeled lens was transferred to 70%
ethanol and incubated overnight. The lens was dehydrated by two 5-hour
incubations in 100% ethanol and dried in 1:2 hexamethyldisilazane
(HMDS; Sigma, St. Louis MO)/ethanol for 1 hour, 2:1 HMDS-ethanol for 1
hour, and two changes of 100% HMDS for 30 minutes each. The lenses
were subsequently transferred to filter paper and placed in a vacuum
dessicator until analysis. The lenses were mounted on stubs with
double-sided tape and sputter coated for 2 minutes with gold-palladium.
Specimens were visualized with a scanning electron microscope (JEOL,
Peabody, MA).
Lens Hydration and Calcium Content
Mice were killed by cervical dislocation, eyes enucleated and
lenses dissected. After vitreous and aqueous humor were blotted, the
lenses were weighed and left at 100°C for 24 hours. The percentage of
hydration was calculated after determination of dry weight. Each dry
lens was digested by adding 50 µl concentrated HCl and incubating for
3 days at room temperature. The sample was then diluted to 500 µl
with distilled, deionized water and the calcium concentration
determined by atomic absorption spectroscopy (model 800; Perkin Elmer,
Norwalk, CT).
Small Eye Mice
Heterozygous mice harboring the Sey<Dey> mutation were obtained
from the Jackson Laboratory (Bar Harbor, ME) and maintained in the
laboratory by backcrossing males to females of the strain FVB/N. Mice
used in the present study have been crossed to FVB/N for 4 to 5
generations. Eyes from mice harboring the Sey<Neu> mutation were a
gift from Yasuhide Furuta and Brigid Hogan, Vanderbilt University
(Nashville, TN).
| Results |
|---|
|
|
|---|
TN4-1 (Fig. 1B)
. In both these cell lines, which were
previously shown to express Pax-6 endogenously,19
32
the
presence of six Pax-6 PD-binding sites upstream of the E1b promoter
(6XPax-6 con) resulted in a large increase in CAT protein expression.
Increasing the levels of Pax-6 in these cell lines by cotransfection of
a Pax-6 expression plasmid resulted in a repression of reporter gene
expression consistent with previous reports.21
Cotransfection of an expression vector producing truncated Pax-6
proteins consisting of either the PD and HD (aa 1286) or PD alone (aa
1140) was much more efficient than full-length Pax-6 in repressing
the expression of the reporter vector containing six Pax-6binding
sites.
|
Cataracts in Mice Transgenic for
A-CrystallinTruncated Pax-6
Transgenes
Because both truncated forms of Pax-6 used in the cotransfection
experiments were able to repress transcriptional activation mediated by
Pax-6 PD-binding sites in lens cell lines, and because patients with
cataract associated with aniridia have been shown to harbor
Pax-6 genes that could give rise to similar
proteins,3
33
we tested the ability of truncated Pax-6
alleles (PD + HD, aa 1286; PD, aa 1140) to disrupt lens function in
a wild-type genetic background using transgenic mice. For these
experiments, the
A-crystallin promoter was used, because it is well
established that it directs moderate to low levels of transgene
expression specifically to lens fiber cells.29
34
Two
independent lines of
A-PD + HD and three lines of
A-PD mice were
generated. One line of
A-PD + HD mice had severe cataracts (Fig. 2B
), whereas the other line had a milder phenotype (data not shown). Two
lines of
A-PD mice had posterior nuclear cataracts (Figs. 2C
2D
). The line of
A-PD mice with clear
lenses at weaning had opacities develop by 16 weeks of age (data not
shown). The correlation between the genotypes and phenotypes described
was 100% in all cases. Nontransgenic littermates were never observed
to have any lens abnormalities.
|
|
A-CrystallinTruncated Pax-6 Transgenic Mice
|
A-CrystallinTruncated Pax-6 Transgenes
A-crystallinPD transgenic mice
expressed easily detectable amounts of truncated PD protein, whereas
neither line of
APD + HD transgenics exhibited levels of transgene
expression detectable by this method.
|
|
| Discussion |
|---|
|
|
|---|
It is well established that aniridia often also involves cataract. Recently, however, it has been noted that individuals with Pax-6 mutations that prematurely truncate the PST domain are especially prone to cataract.23 In fact, a family has been reported in which such a mutation causes cataracts in the absence of overt aniridia.5 Additionally, it has been shown that truncated forms of Pax-6 bind DNA with a higher affinity than wild-type Pax-6 and are capable of blocking the ability of wild-type Pax-6 to transactivate an artificial promoter containing Pax-6 PD-binding sites.18 In the present study, we showed that truncated Pax-6 proteins consisting of either the PD + HD or PD alone could prevent wild-type Pax-6 from activating an artificial promoter consisting of different Pax-6 PD-binding sites upstream of the E1b minimal promoter in lens cell lines. Moreover, truncated Pax-6 protein consisting of PD + HD blocked the activation of this promoter by wild-type Pax-6 in nonlens cells but, curiously, truncated Pax-6 consisting of only the PD did not repress Pax-6 activation of the artificial promoter in transfected nonlens cells. The biochemical basis for this cell line specificity is unclear but may suggest that different truncations can affect Pax-6 function differently in different tissues.
Because the present transfection and previous biochemical
data17
18
suggest that both PD + HD and PD can interfere
with the activity of wild-type Pax-6 in cultured lens cells, we tested
the ability of these truncated proteins to produce a lens phenotype in
vivo by creating transgenic mice that overexpressed these truncated
forms of Pax-6 in the lens under the control of the
A-crystallin
promoter. Both truncations produced transgenic mice in which cataracts
developed, albeit to different extents. These cataracts do not appear
to be due to defects in fiber cell elongation or denucleation, because
these mice have relatively normal lenses at birth. Instead, the fibers
of the cataractous lenses are swollen, more hydrated than normal, and
have elevated levels of total tissue calcium, all of which are typical
of cataractogenesis.41
42
Although the result of the presence of truncated Pax-6 molecules in the
lens is cataract, the initiating event for these cataracts is not
clear. In vitro experiments suggest that truncated Pax-6 molecules bind
to Pax-6binding sites found in the promoters of important lens
proteins37
and block their transcriptional
activity.18
In the simplest interpretation of this
scenario, the cataracts are caused by the absence of one or more gene
products from the lens whose expression is normally dependent on Pax-6
in lens fiber cells. This interpretation is complicated by the fact
that the mouse
A-crystallin promoter used to drive transgene
expression is dependent on Pax-6 for its function.19
It is
possible that expression of PD + HD or PD may be repressing the
transgene promoter itself and that transgene expression may be
pulsatile. It is also possible that the truncated Pax-6 proteins cause
cataracts by disrupting the DNA interactions of nonPax-6
transcription factors, the DNA-binding sites of which overlap with a
Pax-6 site. The overlap of Pax-6binding sites with those of other
factors has been shown previously to result in additive transcriptional
activation in some cases43
and transcriptional repression
in others.17
44
Western blot analysis has demonstrated that a large excess of PD protein is present in the transgenic lens, and competition with endogenous factors for DNA-binding sites is therefore a plausible scenario. Whereas much lower levels of the PD + HD are expressed, it is still possible that it blocks the binding of positively acting transcription factors to DNA because a similarly truncated molecule was demonstrated to have four times the affinity for DNA as wild-type Pax-6.18 Alternatively, it is possible that the Pax-6 transgenes upregulate the expression of wild-type Pax-6 in lens fiber cells, because expression of the Pax-6 gene may be autoregulated by Pax-6 protein.45 However, this possibility is relatively unlikely, because Pax-6 is normally not transcribed in lens fiber cells46 and the truncated Pax-6 proteins used in this study have no transcriptional activation domain.5 18
Unfortunately, the direct effect of truncated Pax-6 proteins on crystallin expression in the transgenic lens is difficult to ascertain. SDS-PAGE analysis of transgenic and wild-type lenses strongly suggests that the relative amount of each crystallin polypeptide made is unchanged, even though the dry mass of transgenic lenses is 77% lower than in wild type lenses. This may suggest that the cataracts observed in the Pax-6 truncationexpressing transgenic mice were due to the transgenes directly affecting the transcription of all crystallin genes equally. Alternatively, the truncated Pax-6 molecules may have affected the expression of other (as yet unidentified) proteins that control the amount of crystallin proteins synthesized by the lens. For instance, because transgenic lenses have elevated levels of calcium, it is possible that the truncated Pax-6 molecules may have altered the expression of proteins important for calcium homeostasis. This would result in alterations in the many signal transduction pathways regulated by calcium,47 which could explain the observed alterations in lens biology. Finally, the global repression of crystallin gene expression in the lens may be a result of the truncated Pax-6 proteins binding to other cellular factors (such as retinoblastoma or TATA boxbinding protein48 ), effectively removing their functions from the cellular pool.
Cataracts are a typical feature of aniridia, with anterior subcapsular and polar opacities being most common.23 That Pax-6 mRNA is expressed principally in the cuboid epithelium on the anterior surface of the developing lens and the proliferative zone located at the lens equator9 22 46 suggests that Pax-6 helps prevent the epithelial to mesenchyme transitions49 that result in anterior polar cataract. However, cortical and posterior polar opacities have also been commonly reported in aniridia.2 50 Unfortunately, even though congenital cataracts have been reported to be more prevalent in aniridia in patients who harbor truncation mutations in the PST domain,23 the clinical description of the cataracts was not reported.
The Sey<Neu> mouse, which harbors a truncation mutation in the PST domain,4 as well as the Sey<Dey> mouse, which harbors a complete deletion of the Pax-6 gene,12 do not exactly recapitulate the phenotype of the human aniridic eye. Most notably, the lenses of these mice generally remain clear throughout life, with only occasional cataractous changes seen in the anterior epithelium. It is likely that the differences in the lens phenotype between mice and humans harboring Pax-6 truncation mutations reflect either differences in the time that lens cells are exposed to the truncated proteins or differences in the duration of the life span of individual lens fiber cells.
In the present study, we successfully generated both cortical and posterior polar lens opacities by ectopically expressing truncated forms of Pax-6 in lens fiber cells. Because some truncated Pax-6 proteins bind to DNA with a fourfold higher affinity than wild-type Pax-6 and can block the function of wild-type Pax-6 in transfection tests, it can be proposed that the cataractous changes seen in the lenses of patients with aniridia harboring truncation mutations of Pax-6 could be due to a dominantnegative effect. However, it is still possible that the predominant cause of aniridia-associated cataract is either haploinsufficiency of Pax-6 in lens cells or a secondary effect caused by the other eye diseases seen in these patients. A definitive answer to this question awaits better clinical characterization of aniridia-associated cataract in patients whose underlying Pax-6 mutation has been determined.
| Conclusions |
|---|
|
|
|---|
|
| Acknowledgements |
|---|
| Footnotes |
|---|
Supported by a grant from the Knights Templar Eye Foundation (MKD), Grant RO1 EY12221-01 from The National Eye Institute (MKD), a Research to Prevent Blindness Career Development Award (AC), intramural research support (1Z01EY0012617) from The National Eye Institute (JP); and National Institutes of Health IDEA Grant RR11820 to the University of Delaware.
Submitted for publication May 20, 1999; revised August 16, 1999; accepted September 23, 1999.
Commercial relationships policy: N.
Corresponding author: Melinda K. Duncan, Department of Biological Sciences, The University of Delaware, 331 Wolf Hall, Newark, DE 19716. duncanm{at}udel.edu
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
Z. Firtina, B. P. Danysh, X. Bai, D. B. Gould, T. Kobayashi, and M. K. Duncan Abnormal Expression of Collagen IV in Lens Activates Unfolded Protein Response Resulting in Cataract J. Biol. Chem., December 18, 2009; 284(51): 35872 - 35884. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Hingorani, K. A. Williamson, A. T. Moore, and V. van Heyningen Detailed Ophthalmologic Evaluation of 43 Individuals with PAX6 Mutations Invest. Ophthalmol. Vis. Sci., June 1, 2009; 50(6): 2581 - 2590. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Landgren, A. Blixt, and P. Carlsson Persistent FoxE3 Expression Blocks Cytoskeletal Remodeling and Organelle Degradation during Lens Fiber Differentiation Invest. Ophthalmol. Vis. Sci., October 1, 2008; 49(10): 4269 - 4277. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Yan, W.-B. Liu, J. Qin, J. Liu, H.-G. Chen, X. Huang, L. Chen, S. Sun, M. Deng, L. Gong, et al. Protein Phosphatase-1 Modulates the Function of Pax-6, a Transcription Factor Controlling Brain and Eye Development J. Biol. Chem., May 11, 2007; 282(19): 13954 - 13965. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Grocott, V. Frost, M. Maillard, T. Johansen, G. N. Wheeler, L. J. Dawes, I. M. Wormstone, and A. Chantry The MH1 domain of Smad3 interacts with Pax6 and represses autoregulation of the Pax6 P1 promoter Nucleic Acids Res., February 16, 2007; 35(3): 890 - 901. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Ouyang, Y.-C. Shen, L.-K. Yeh, W. Li, B. M. Coyle, C.-Y. Liu, and M. E. Fini Pax6 overexpression suppresses cell proliferation and retards the cell cycle in corneal epithelial cells. Invest. Ophthalmol. Vis. Sci., June 1, 2006; 47(6): 2397 - 2407. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Owsley, G. McGwin, G. R. Jackson, D. C. Heimburger, C. J. Piyathilake, R. Klein, M. F. White, and K. Kallies Effect of short-term, high-dose retinol on dark adaptation in aging and early age-related maculopathy. Invest. Ophthalmol. Vis. Sci., April 1, 2006; 47(4): 1310 - 1318. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Haubst, J. Berger, V. Radjendirane, J. Graw, J. Favor, G. F. Saunders, A. Stoykova, and M. Gotz Molecular dissection of Pax6 function: the specific roles of the paired domain and homeodomain in brain development Development, December 15, 2004; 131(24): 6131 - 6140. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. W. Reneker, Q. Chen, A. Bloch, L. Xie, G. Schuster, and P. A. Overbeek Chick {delta}1-Crystallin Enhancer Influences Mouse {alpha}A-Crystallin Promoter Activity in Transgenic Mice Invest. Ophthalmol. Vis. Sci., November 1, 2004; 45(11): 4083 - 4090. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. K. Duncan, L. Xie, L. L. David, M. L. Robinson, J. R. Taube, W. Cui, and L. W. Reneker Ectopic Pax6 Expression Disturbs Lens Fiber Cell Differentiation Invest. Ophthalmol. Vis. Sci., October 1, 2004; 45(10): 3589 - 3598. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Rajaram and T. K. Kerppola Synergistic Transcription Activation by Maf and Sox and Their Subnuclear Localization Are Disrupted by a Mutation in Maf That Causes Cataract Mol. Cell. Biol., July 1, 2004; 24(13): 5694 - 5709. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. K. Chauhan, Y. Yang, K. Cveklova, and A. Cvekl Functional interactions between alternatively spliced forms of Pax6 in crystallin gene regulation and in haploinsufficiency Nucleic Acids Res., March 12, 2004; 32(5): 1696 - 1709. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. K. Chauhan, Y. Yang, K. Cveklova, and A. Cvekl Functional Properties of Natural Human PAX6 and PAX6(5a) Mutants Invest. Ophthalmol. Vis. Sci., February 1, 2004; 45(2): 385 - 392. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Pratt, J. C. Quinn, T. I. Simpson, J. D. West, J. O. Mason, and D. J. Price Disruption of Early Events in Thalamocortical Tract Formation in Mice Lacking the Transcription Factors Pax6 or Foxg1 J. Neurosci., October 1, 2002; 22(19): 8523 - 8531. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Goudreau, P. Petrou, L. W. Reneker, J. Graw, J. Loster, and P. Gruss Mutually regulated expression of Pax6 and Six3 and its implications for the Pax6 haploinsufficient lens phenotype PNAS, June 25, 2002; 99(13): 8719 - 8724. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. K. Chauhan, W. Zhang, K. Cveklova, M. Kantorow, and A. Cvekl Identification of Differentially Expressed Genes in Mouse Pax6 Heterozygous Lenses Invest. Ophthalmol. Vis. Sci., June 1, 2002; 43(6): 1884 - 1890. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. K. Chauhan, N. A. Reed, W. Zhang, M. K. Duncan, M. W. Kilimann, and A. Cvekl Identification of Genes Downstream of Pax6 in the Mouse Lens Using cDNA Microarrays J. Biol. Chem., March 22, 2002; 277(13): 11539 - 11548. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Lauderdale, J. S. Wilensky, E. R. Oliver, D. S. Walton, and T. Glaser 3' deletions cause aniridia by preventing PAX6 gene expression PNAS, November 16, 2000; (2000) 240398797. [Abstract] [Full Text] |
||||
![]() |
M. Duncan, Z Kozmik, K Cveklova, J Piatigorsky, and A Cvekl Overexpression of PAX6(5a) in lens fiber cells results in cataract and upregulation of (alpha)5(beta)1 integrin expression J. Cell Sci., January 9, 2000; 113(18): 3173 - 3185. [Abstract] [PDF] |
||||
![]() |
J. D. Lauderdale, J. S. Wilensky, E. R. Oliver, D. S. Walton, and T. Glaser 3' deletions cause aniridia by preventing PAX6 gene expression PNAS, December 5, 2000; 97(25): 13755 - 13759. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |